GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Float Percentage Of Total Shares Outstanding

Protalix BioTherapeutics (FRA:PBDA) Float Percentage Of Total Shares Outstanding : 95.61% (As of Dec. 15, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Protalix BioTherapeutics's float shares is 70.40 Mil. Protalix BioTherapeutics's total shares outstanding is 73.63 Mil. Protalix BioTherapeutics's float percentage of total shares outstanding is 95.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Protalix BioTherapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Protalix BioTherapeutics's Institutional Ownership is 1.16%.

Protalix BioTherapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Protalix BioTherapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=70.40/73.63
=95.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
SKYE CRDF TELO CHRS ADVM IFRX RPTX OTLK VIGL VTYX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
PLX:USA
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Website
https://www.protalix.com
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines